[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100597173":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":10,"responsibleParty":18,"collaborators":10,"id":20,"slug":21,"hasResults":22,"nctId":23,"briefTitle":24,"officialTitle":24,"acronym":10,"eligibilityCriteria":25,"healthyVolunteers":22,"sex":26,"minAge":27,"maxAge":10,"enrollmentInfo":28,"targetDuration":10,"studyType":31,"phases":10,"briefSummary":32,"conditions":33,"keywords":35,"overallStatus":38,"whyStopped":10,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":10},{"fullName":5,"class":6},"Shanghai East Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Research group",null,"It is expected to include 60 patients with suspected hepatic space-occupying lesions , and the tracer radiation used in the study is extremely small and will not have any physiological effects on the subjects.",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Jie Ding, MD","CONTACT","086-38804518","dingjie940406@163.com",{"type":19,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100597173","the-diagnostic-efficacy-and-lesion-detection-advantages-of-18f-fdg-petcontrast-enhanced-mri-in-malignant-liver-lesions-100597173",false,"NCT07055048","The Diagnostic Efficacy and Lesion Detection Advantages of 18F-FDG PET\u002FContrast-enhanced MRI in Malignant Liver Lesions","Inclusion Criteria:\n\n* Age ≥18 years;\n* Patients with suspected liver metastases or hepatic lesions,\n* Ability to undergo 18F-FDG PET\u002FMRI examination;\n* Willingness to comply with study protocols.\n\nExclusion Criteria:\n\n* Patients with a history of allergic reactions to MRI contrast agents;\n* Pregnant or lactating women;\n* Patients with severe comorbidities, including: Cardiac disease，Renal failure，or Hepatic failure (Child-Pugh C);\n* Patients unable to cooperate with PET\u002FMRI procedures.","ALL","18 Years",{"count":29,"type":30},60,"ESTIMATED","OBSERVATIONAL","Liver disease, a major global health burden, ranges from mild dysfunction to severe conditions like cirrhosis and hepatocellular carcinoma (HCC), the fifth most common cancer. Accurate diagnosis of liver lesions-distinguishing benign from malignant-is vital for treatment planning. Conventional imaging (ultrasound, CT, MRI) has limitations in sensitivity and detecting small metastases. PET\u002FCT combines metabolic and anatomical data but struggles with small lesions and cirrhotic livers.\n\n18F-FDG PET\u002FMRI with contrast-enhanced MRI may improve diagnostic accuracy, but its clinical benefits remain uncertain. Further research is needed to evaluate its performance, impact on patient outcomes, and cost-effectiveness in liver disease management.",[34],"Liver Cancer, Adult",[36,37],"PET\u002FMR","liver cancer","NOT_YET_RECRUITING","2025-07-03",{"date":41,"type":42},"2025-07-08","ACTUAL",{"date":44,"type":30},"2025-06-30",{"date":46,"type":30},"2025-12-31",{"name":5,"class":6}]